Dideoxycytidine for AIDS
Executive Summary
HHS is seeking an industry sponsor to collaborate in the preclinical and clinical development of the antiviral for treatment of AIDS. In the Oct. 14 Federal Register, HHS reported that National Cancer Institute scientists have shown dideoxycytidine "is effective in inhibiting in vitro growth of HTLV-III, the etiologic agent of AIDS." The agency said the industry sponsor will be granted an exclusive royalty-bearing license, while the U.S. government will receive "reasonable royalties".